Apogee Therapeutics doses first volunteers in Phase 1 trial of APG808 for COPD and asthma

Apogee Therapeutics, Inc.

First participants dosed in Phase 1 healthy volunteer trial of APG808, a half-life extended IL-4Rα mAb.
Preclinical data suggest potential for dosing every 6-8 weeks vs. every 2 weeks for other biologics in development.
Interim safety and PK data from healthy volunteers anticipated in second half of 2024.
APG808 is the second product candidate to enter clinic, following positive interim results from Phase 1 trial of APG777.
Company plans to initiate Phase 1b asthma trial in 1H 2025 and Phase 2 COPD trial in 2025, pending positive Phase 1 results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.